Fulgent Genetics (FLGT) Receivables - Net (2015 - 2026)

Fulgent Genetics has reported Receivables - Net for 12 years, with the latest figure at $64.9 million in Q2 2026.

• Quarterly Receivables - Net fell 15.87% year-over-year to $64.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $64.9 million (down 15.87% YoY) and the FY2025 annual result came in at $84.8 million, up 22.81% from the prior year.
• Receivables - Net fell to $64.9 million in Q2 2026 per FLGT's latest filing, from $69.3 million in the prior quarter.
• Over five years, Receivables - Net peaked at $160.3 million in Q1 2022 and troughed at $34.8 million in Q2 2023.
• A 5-year average of $72.4 million and a median of $67.0 million in 2024 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2023 and 2024: Receivables - Net slumped 73.89% in 2023, then jumped 62.52% in 2024.
• Over 5 years, Receivables - Net stood at $52.7 million in 2022, then slipped by 3.07% to $51.1 million in 2023, then soared by 34.99% to $69.0 million in 2024, then rose by 22.81% to $84.8 million in 2025, then decreased by 23.39% to $64.9 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $64.9 million, $69.3 million, and $84.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.